Therapeutic Effect of Mesenchymal Stem Cells Overexpressing Interleukin-10 on Inflammatory Bowel Disease
- Author:
Xin LU
1
;
Tao-Ran ZHAO
1
;
Hai-Qin CHENG
1
;
Xue-Wei LI
1
;
Ting LIANG
1
;
Xin-Rui XU
1
;
Zi-Xuan HU
1
;
Chun-Hong ZHANG
1
;
Chun-Ting CHEN
1
;
Lei WANG
1
;
Jun XIE
1
;
Zhi-Zhen LIU
1
;
Hong ZHAO
1
;
Li-Hui MA
2
Author Information
- Publication Type:Journal Article
- Keywords: cytokines secretion; inflammatory bowel disease (IBD); interleukin-10 (IL-10); mesenchymal stem cells (MSCs); T helper cells differentiation
- From: Chinese Journal of Biochemistry and Molecular Biology 2022;38(9):1202-1212
- CountryChina
- Language:Chinese
- Abstract: Inflammatory bowel disease (IBD) is an, intractable inflammatory autoimmune disease characterized by T-cell infiltration to the colon. Mesenchymal stem cells (MSCs), owing to their immunosuppressive capabilities, have the potential to rescue IBD. But the therapeutic effectiveness of MSCs is sometime thwarted by their variable immunomodulatory ability in vivo. In the present study, we produced engineered MSCs that secrete interleukin10 (IL-10) and evaluated their therapeutic potential in IBD mouse model. The MSCs maintained the phenotype and cell proliferation rate after overexpression of IL-10 by lentivirus (LV) infection. Immune cells and MSCs in vitro co-culture systems exhibited that relative to unmodified MSCs, immune cells co-cultured with IL-10-overexpressing MSCs had significantly lower numbers of T helper 1 cells (Th1) and T helper 17 cells (Th17) (P<0.05), the content of TNF-α in the supernatant of macrophage cells co-cultured with MSCs overexpressing IL-10 was significantly decreased (P<0.0001). Tail vein injection of the IL-10 overexpressing MSCs achieved a better therapeutic effect in the dextran sodium sulfate (DSS) induced colitis mouse model than that of the unmodified MSCs, as indicated by colon length, disease activity index (DAI) and colonic cytokines expression. The experimental results were statistically different (P>0.05). Overall, LV induced MSCs overexpressing IL-10 might be a promising alternative therapeutic option for the treatment of IBD.
